CASE REPORT

Epstein-Barr virus infection associated polymyositis and coronary artery dilation

Liping Teng¹, Chencong Shen¹, Weizhong Gu², Jianqiang Wu¹, Meiping Lu¹,³* and Xuefeng Xu¹,³*

Abstract

Background: Epstein-Barr virus (EBV) infects more than 90% of the population worldwide. However, chronic active EBV infection (CAEBV) is one of the EBV-positive T- or NK-lymphoproliferative diseases with high morbidity and mortality. Here, we report a case of a 9-year girl with CAEBV, successively presenting with polymyositis and coronary artery dilation (CAD).

Case presentation: The girl complained of fatigue for more than 1 month. Muscle strength examinations had no abnormal findings. Blood chemistries showed elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK). Magnetic resonance imaging (MRI) showed spotty high-intensity signals in thigh muscles, and electromyogram suggested myogenic damage. The significant findings were positive EBV antibodies (EBVEA-IgG, EBVCA-IgG, and EBVNA-IgG), increased EBV DNA copies in B, T, and NK cells, and positive EBV-encoded small RNA in biopsy muscle specimen. The girl received ganciclovir, intravenous immunoglobulin, and methylprednisolone, and her symptoms improved. On the 45th day of hospitalization, echocardiograph revealed CAD. She received additional anticoagulants and Tocilizumab. Her condition improved and continued to be followed up at the clinic preparing for hematopoietic stem cell transplantation.

Conclusions: This is the first reported case of CAEBV successively with polymyositis and CAD. This case makes the diagnoses of autoimmune diseases in children more complicated. Careful investigation of hidden CAEBV should be recommended in children with atypical polymyositis or CAD.

Keywords: Children, Epstein-Barr virus, Polymyositis, Coronary artery dilation

Background

Epstein-Barr virus (EBV) is a ubiquitous double-stranded DNA virus, infecting more than 90% of the population worldwide [1]. Most of EBV infections induce subclinical or acute infectious mononucleosis in immunocompetent individuals with transient proliferation of EBV-infected B lymphocytes accompanied by excessive response of EBV-specific cytotoxic T lymphocytes [2]. However, chronic active EBV infection (CAEBV) is a severe disease with high morbidity and mortality, especially in East Asian countries. In CAEBV, EBV-infected T or natural killer (NK) cells clonally proliferate and infiltrate multiple organs, leading to fatal complications such as multi-organ failure, polymyositis, coronary artery aneurysms, vasculitis of the central nervous system, and malignant lymphomas as well as hemophagocytic lymphohistiocytosis [3–6].

No previous reports in the existing literature have definite cases of EBV infection manifesting as both polymyositis and coronary artery dilation (CAD). We described here a rare pediatric case with EBV infection, successively presenting with polymyositis and CAD. The case report aims to make pediatricians pay more attention to the complexity of pediatric cases with EBV infection.
Case presentation

In July 2020, a 9-year girl was admitted to the Department of Gastroenterology in our hospital for fatigue for more than 1 month, and abnormal liver function for 2 days. Physical examination on admission revealed visible tonsils, and cervical lymphadenectasis; no rales in both lungs; no murmurs in her heart; no positive signs on nervous system; and no skin rash. The liver was palpated 3 cm below the costal margin. Muscle strength examinations had no abnormal findings. When she was 3 years old, she got thrombocytopenic purpura and received oral steroid therapy for 3 months.

Peripheral blood counts showed WBC $5.7 \times 10^9/L$ with 70% neutrophils, 23% lymphocytes, Hgb 102 g/L and a platelet count $223 \times 10^9/L$. Blood chemistries indicated alanine aminotransferase (ALT) of 224 U/L, aspartate aminotransferase (AST) of 417 U/L, lactate dehydrogenase (LDH) of 1363 U/L, creatine kinase (CK) of 16,418 U/L, CKMB of 441 U/L, and ferritin of 123 mg/L (Fig. 1). EBV IgM and cytomegalovirus (CMV) IgM were negative, and EBV-1gG, EBVCA-IgG, EBVNA-IgG were positive (Table 1). Antinuclear antibodies, coagulation function, thyroid function, and immunoglobulin were within normal ranges. Hepatitis viruses B and C, and human immunodeficiency virus were negative. Detecions of myositis specific antibodies were negative. Electromyogram suggested myogenic damage, and echocardiography showed no coronary artery dilation. Chest CT showed small patchy shadow in left upper lobe, and lung function testing was normal. The magnetic resonance imaging (MRI) showed spotty high-intensity signals in both of thigh muscles such as adductor muscles, and femoral quadriceps muscles indicating muscle inflammation (Fig. 2A). Bone marrow aspiration did not show leukemic changes and hemophagocytosis.

Table 1  Clinical characteristics of the patient on admission

| Clinical variables | Values |
|-------------------|--------|
| IgG (g/L)         | 20.8   |
| IgG1 (g/L)        | 24.8   |
| IgG2 (g/L)        | 1.87   |
| IgG3 (g/L)        | 0.99   |
| IgG4 (g/L)        | 0.01   |
| IgM (g/L)         | 2.49   |
| IgA (g/L)         | 1.98   |
| IgE (U/L)         | 4.3    |
| CD 20 (%)         | 4.91   |
| CD3 (%)           | 73.46  |
| CD4 (%)           | 32.06  |
| CD8 (%)           | 37.58  |
| CD3–CD16+CD56+ (%)| 12.99  |
| CD4/CD8           | 0.85   |
| ANA               | <1.80  |
| RF (U/ml)         | 255    |
| EBV–IgG           | +      |
| EBVCA–IgG         | > 750 U/mL |
| EBVNA–IgG         | > 600 U/mL |
| CMV–IgM           | –      |
| Plasma (day 7)    | $1.09 \times 10^4$ |
| Plasma (day 23)   | $6.96 \times 10^3$ |
| Plasma (day 39)   | $9.55 \times 10^2$ |
| Plasma (day 55)   | $1.22 \times 10^3$ |
| B cells (day 7, copies/10^6 cells) | $1.37 \times 10^4$ |
| T cells (day 7, copies/10^6 cells) | $9.02 \times 10^5$ |
| NK cells (day 7, copies/10^6 cells) | $1.64 \times 10^4$ |

*ANA antinuclear antibody, CMV cytomegalovirus, EBVEA Epstain-Barr virus early antigen, EBVCA Epstain-Barr virus capsid antigen, EBVNA Epstain-Barr virus nuclear antigen, --, negative; +, positive*
One week after admission, the girl was suspected of polymyositis, and transferred to Department of Rheumatology and Immunology. Considering her inconsistence with typical polymyositis features, we further performed muscle biopsy and whole medical exons analysis. Histopathological findings of thigh muscle biopsy demonstrated a large amount of inflammatory cells infiltrations with predominant CD3+, CD4+, and CD8+ T lymphocytes (Fig. 3A–D). In situ hybridization indicated the expression of EBV-encoded small RNA (EBER) in the lymphocytes (Fig. 3E, F). EBV DNA detections in B, T, and NK cells were positive (Table 1). Whole body 18 F-FDG (Fluoro-D-Glucose) PET/MRI suggested multiple muscles’ patchy abnormal signals and an increased
FDG metabolism. Although the girl had elevated EBV genome in peripheral B, T, and NK cells, positive EBER in biopsy muscle specimen, and abnormal liver function, her clinical symptoms only persisted for less than 2 months, which did not meet the diagnostic criteria of chronic active EBV infections (CAEBV). Therefore, she was diagnosed as EBV-related polymyositis, and treated with ganciclovir, intravenous immunoglobulin (once a month), methylprednisolone (1 mg/kg/d), and other supportive treatment. Twenty days after admission, her temperature turned normal, CK, CKMB, and ALT significantly reduced, and her condition improved (Fig. 1). However, on the 45th day of hospitalization, repeated echocardiograph revealed coronary artery dilation (CAD). The mean luminal diameters of left and right coronary arteries were 6.5 mm, and 5.8 mm, respectively. CAD was further confirmed by contrast-enhanced computed tomography angiography (CTA) without vascular...

**Fig. 3** Histopathological findings of thigh muscle biopsy specimens. The inflammatory infiltrations were mainly composed of CD3+ (A, brown signal), CD4+ (B, brown signal), and CD8+ (C, brown signal) T lymphocytes, and CD20+ (D, brown signal) cells were also observed. The predominantly infiltrated lymphocytes were T cells. EBV-encoded small RNA (EBER) positivity was observed in the lymphocytes by in situ hybridization (E, F, brown signal)
lesions outside the heart (Fig. 2B, C). The girl was treated with oral aspirin and clopidogrel. During our consecutive echocardiograph monitoring, left and right coronary arteries were found to be progressively dilated (about 2 mm increases within a week). She was suspected of vasculitis and infused with Tocilizumab (8 mg/kg/month). Her CAD did not worsen, and continued anticoagulation and Tocilizumab treatments, while her oral steroids gradually tapered. After about 2 months of hospitalization, the patient’s symptoms improved, and her condition was stable. Therefore, she was discharged, and continued to be followed up at the clinic preparing for hematopoietic stem cell transplantation.

Discussion and conclusions

Clinical diversification of EBV infections, especially CAEBV would make the diagnoses of autoimmune diseases more challenging. We herein described a pediatric case with EBV infection who successively presented with polymyositis and CAD. She was treated with steroid, regular immunoglobulin transfusion, and biologic agent.

The patient had high EBV DNA copies in peripheral B, T, and NK cells, positive EBER in muscle specimen, and abnormal liver function. Although her clinical symptoms on admission only persisted for less than 2 months, successive polymyositis and CAD suggested the presence of CAEBV. Skeletal muscle involvement in CAEBV is relatively rare, and polymyositis or generalized myositis is also rare [7]. In general, double negative (DN, CD4- and CD8-) T-cells do not populate in normal human muscles. However, EBV+DN T-cells infiltrated muscle tissues during the course of CAEBV, resulting in myositis [3]. Some patients showed steroid non-responsive chronic progressive generalized myositis, predominantly intramuscular infiltrating CD3+, EBER+, DN T cells [7]. This pattern is significantly different from CD8+ (single positive) T-cell dominance in polymyositis, and CD4+T cell dominance in dermatomyositis [7]. Kobayashi et al. reported a case of CAEBV with EBER+, CD8+ T-cell infiltrations in the brachialis muscle specimen. The patient was treated with prednisone and immunosuppressant, and her CK levels and EBV-DNA copies of the peripheral mononuclear cells rapidly decreased [8]. There are few reports about CAEBV combined with myositis. Our case showed predominant CD3+, CD4+, and CD8+T lymphocytes infiltrations in muscle specimen with positive EBER, further confirming CAEBV. Her elevated CK and symptoms significantly improved through steroid and antiviral treatments. Unfortunately, as the polymyositis improved, she developed coronary artery dilation.

About 10% pediatric cases with CAEBV had cardiovascular complications, including pericarditis, myocarditis, and mitral valve regurgitation [9]. The cardiovascular lesions also presented with pulmonary arterial hypertension and systemic vasculitis [10]. Fujimoto et al. reported two cases of ulcerative vasculitis in methotrexate-prescribed rheumatoid arthritis patients, simulating rheumatoid vasculitis [11]. EBER on their skin biopsies confirmed the diagnosis of EBV-related vasculitis instead of rheumatoid vasculitis [11]. Additionally, a high positive rate of antineutrophil cytoplasmic autoantibody (ANCA) in the sera positive for EBV IgM suggested that EBV infection might trigger the relapse of ANCA-associated vasculitis [12]. Furthermore, the brain biopsy from a 75-year woman with EBV-associated vasculitis who had a history of rheumatoid arthritis, showed perivascular lymphocytic infiltration with EBER in the parenchyma and meninx [6]. This further indicated that EBV can almost invade all the vessels in the body.

Notably, CAEBV may cause aneurysmal dilation of the lumens in other lager vessel such as carotid and subclavian arteries, abdominal aorta and its major branches, in addition to coronary arteries [13]. In view of the EBER-positive lymphocytes detected in the vasa vasorum, these arterial lesions were obviously different from Kawasaki disease [13]. Myocardial EBV infection can also induce acute myocarditis with heart failure, necrotizing coronary vasculitis, and multiple left ventricular aneurysms. The elevated myocardial viral load, positive EBV protein in cardiomyocytes, and inflamed coronary intramural vessels confirmed the causal role of EBV [14]. Cardiovascular lesions in CAEBV could be strongly associated with EBV-infected T or NK lymphocyte infiltration and injuries in the vessel walls, and EBV-induced high levels of inflammatory cytokines [5]. Our case developed CAD when her clinical symptoms improved. Furthermore, ten days after confirming CAD, plasma EBV DNA copies slightly increased from $9.55 \times 10^2$ to $1.22 \times 10^3$. This phenomenon could indicate the direct infiltrations of EBV-infected lymphocytes into vascular wall or immune dysfunction induced by EBV. Since we did not perform histological examination of the damaged coronary arteries, the underlying mechanism needs to be further investigated. On the other hand, our patient only presented with mild fever and swollen lymph nodes in the neck, which did not meet the diagnosis of Kawasaki disease. Thus, it is reasonable to speculate that CAD might be caused by vasculitis induced by EBV infection instead of Kawasaki disease.

Conclusions

Patients with CAEBV may have various symptoms and clinical courses. We herein reported the first case of CAEBV successively presenting with polymyositis and CAD. This case further suggests that CAEBV could make
the diagnoses of autoimmune diseases in children more complicated. Careful investigation of hidden CAEBV should be recommended in children with atypical polymyositis or coronary artery dilation.

Abbreviations
CAEBV: Chronic active Epstein-Barr virus infection; CAD: Coronary artery dilation; CD: Cluster of differentiation; EBER: EBV-encoded small RNA; EBV: Epstein-Barr virus; NK: Natural killer.

Acknowledgements
We thanked YM Tang for his treatment suggestion.

Authors’ contributions
LPT and XFX conceptualized and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted. CCS, WZG, and JQW carried out the initial analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted. MPL designed the data collection instruments, coordinated, and supervised data collection, and critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
This work was supported by funds from the National Natural Science Foundation of China (81871220), and the Fundamental Public Benefit Research Plan of Zhejiang Province (LGC20H040001). The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethic Review Board of Children’s Hospital, Zhejiang University School of Medicine (2020-IRB-073).

Consent for publication
Written informed consent was obtained from the patient’s parent for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Rheumatology Immunology & Allergy, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310003 Hangzhou, People’s Republic of China. 2 Department of Pathology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310003 Hangzhou, People’s Republic of China. 3 Department of Pulmonary Medicine, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310003 Hangzhou, People’s Republic of China.

Received: 11 May 2021   Accepted: 1 March 2022
Published online: 07 March 2022

References
1. Fujiwara S, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakuguchi H. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int. 2014;56(2):159–66.
2. Arai A. Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr. 2019;7:14.
3. Tsutsumi S, Ohga S, Nomura A, Takada H, Sakai S, Ohshima K, Sumimoto K, Hara T. CD4+CD8− T-cell polymyositis in a patient with chronic active Epstein-Barr virus infection. Am J Hematol. 2002;71(3):211–5.
4. Chen KY, Li XZ, Lin Q, Zhu Y, Shen YN, Xu QY, Zhu XM, Bai ZJ, Li Y. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report. BMC Pediatr. 2020;20(1):456.
5. Xiao H, Hu B, Luo R, Hu H, Zhang J, Kuang Z, Zhang R, Li L, Liu G. Chronic active Epstein-Barr virus infection manifesting as coronary artery aneurysm and urethra. Viril J. 2020;17(1):166.
6. Kano K, Katayama T, Takeguchi S, Asanome A, Takahashi K, Saito T, Sawada J, Saito M, Aneri R, Kamada K, et al. Biopsy-proven case of Epstein-Barr virus (EBV)-associated vasculitis of the central nervous system. Neuropathology. 2017;37(3):259–64.
7. Uchiyama T, Arai K, Yamamoto-Tabata T, Hira K, Kishimoto K, Nakamura Y, Hattori T. Generalized myositis mimicking polymyositis associated with chronic active Epstein-Barr virus infection. J Neurol. 2005;252(5):519–25.
8. Kobayashi N, Mitsui T, Ogawa Y, Iriuchishima H, Takazawa M, Yohokahama A, Saicho T, Koiso H, Tsukamoto N, Murakami H, et al. A rare case of chronic active Epstein-Barr virus (EBV) infection accompanied by the infiltration of EBV-infected CD8+ T cells into the muscle. J Pediatr Hematol Oncol. 2018;40(3):e171-5.
9. Lu G, Xie ZD, Zhao SY, Ye LJ, Wu RH, Liu CY, Yang S, Jin YK, Shen KL. Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases. Chin Med J. 2009;122(3):262–6.
10. Li H, Xu L, Peng H, Liu Y, Li X, Wang H, Qin Y. Chronic active Epstein-Barr virus infection with systemic vasculitis and pulmonary arterial hypertension in a child. Front Pediatr. 2019;7:219.
11. Fujimoto M, Kaku Y, Yamakawa N, Kawabata D, Ohmura K, Koyanagi I, Mimori T, Kabashima K, Haga H. Methotrexate-associated EBV-positive vasculitis in the skin: a report of two cases simulating rheumatoid vasculitis. J Cutan Pathol. 2016;43(6):520–5.
12. Xu P, Lin S, Wei L, Shang W. Antineutrophil cytoplasmic antibody-associated vasculitis associated with Epstein-Barr virus infection: a case report and review of the literature. Infection. 2014;42(3):591–4.
13. Murakami K, Ohsawa M, Hu SX, Kann H, Aozasa K, Nose M. Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. Arthr-itis Rheum. 1998;41(2):369–73.
14. Chimienti C, Verardo R, Grande C, Francoce M, Frustaci A. Infant-ri-like myocarditis with coronary vasculitis and aneurysm formation caused by Epstein-Barr virus infection. ESC Heart Fail. 2020;7(3):938–41.